StockData
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. (AMLX) stock

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$27.52−0.28 (-1.01%)

Close on Nov 17, 2026Market cap $3.07BP/E –Yield –

Amylyx Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Amylyx Pharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $0. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $380.79M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$87.37M-77.1%
FY2023Dec 31, 2023$380.79M+1612.9%
FY2022Dec 31, 2022$22.23M+7700.0%
FY2021Dec 31, 2021$285.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$0-100.0%
Q3 FY2024Sep 30, 2024$416.00K-99.6%
Q2 FY2024Jun 30, 2024-$1.02M-101.0%
Q1 FY2024Mar 31, 2024$88.64M+24.1%
Q4 FY2023Dec 31, 2023$108.45M+395.5%
Q3 FY2023Sep 30, 2023$102.69M+29666.1%
Q2 FY2023Jun 30, 2023$98.22M–
Q1 FY2023Mar 31, 2023$71.43M+24962.5%
Q4 FY2022Dec 31, 2022$21.89M–
Q3 FY2022Sep 30, 2022$345.00K–
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$285.00K–

More Amylyx Pharmaceuticals figures

See a number that looks wrong?